<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139369">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01666782</url>
  </required_header>
  <id_info>
    <org_study_id>CIC 1336-B12-1</org_study_id>
    <nct_id>NCT01666782</nct_id>
  </id_info>
  <brief_title>Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy</brief_title>
  <acronym>IMMUNE</acronym>
  <official_title>A Randomized Pilot Study Comparing High-Dose Influenza Vaccine to Standard-Dose Influenza Vaccine in Adult Oncology Patients Less Than 65 Years Receiving Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saad Jamshed MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rochester General Hospital</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and immunogenicity of high dose influenza vaccine has not been studied in young
      patients receiving chemotherapy. This study will evaluate and compare the immunogenicity and
      safety of high dose influenza to standard dose influenza vaccine in adult oncology patients
      who are younger than 65 years old receiving chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The Geometric Mean Titer (GMT) of high-dose influenza vaccine vs the standard trivalent influenza vaccine in adult subjects on chemotherapy who are less than 65 years old.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure Geometric Mean Titer (GMT) before and after vaccination at day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The seroprotection rate of high-dose influenza vaccine vs standard trivalent influenza vaccine in adult subjects on chemotherapy less than 65 years old.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The seroconversion rate of high-dose influenza vaccine versus standard trivalent influenza vaccine in adult subjects on chemotherapy less than 65 years old.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate and compare the local and systemic adverse events to both vaccines.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cancer</condition>
  <condition>Influenza Viral Infections</condition>
  <arm_group>
    <arm_group_label>High-Dose Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard Trivalent Influenza Vaccine</intervention_name>
    <description>Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.</description>
    <arm_group_label>Standard Trivalent Influenza Vaccine</arm_group_label>
    <other_name>Fluzone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-Dose Influenza Vaccine</intervention_name>
    <description>Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.</description>
    <arm_group_label>High-Dose Influenza Vaccine</arm_group_label>
    <other_name>Fluzone High-Dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years old to less than 65 years old

          2. Subjects with malignancy must be receiving chemotherapy

          3. Medically stable

          4. Able to understand and willingness to sign a written informed consent

          5. Able to comply with study procedures

          6. Life expectancy of more than 3 months

          7. Adequate organ function:

               -  ANC &gt;1000/mm3

               -  Platelet &gt;100,000/uL

               -  Creatinine &lt;2 mg/dL

               -  AST and ALT &lt;3 times the ULN

        Exclusion Criteria:

          1. Allergy to eggs

          2. Prior allergy to Influenza Vaccine

          3. History of Guillain-Barre Syndrome

          4. Current febrile illness

          5. Other immunosuppressive disease (recipients of solid organ transplant, uncontrolled
             HIV)

          6. Autologous or Allogenic Stem Cell Transplant with in a year

          7. Current immunotherapy or immunochemotherapy in the last 6 months (rituximab or
             ofatumumab)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saad Jamshed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saad Jamshed, MD</last_name>
    <phone>585-922-4020</phone>
    <email>saad.jamshed@rochestergeneral.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saad Jamshed, MD</last_name>
      <phone>585-922-4020</phone>
      <email>saad.jamshed@rochestergeneral.org</email>
    </contact>
    <investigator>
      <last_name>Saad Jamshed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lipson Cancer Center Linden Oaks Medical Campus</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14625</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saad Jamshed, MD</last_name>
      <phone>585-922-4020</phone>
      <email>saad.jamshed@rochestergeneral.org</email>
    </contact>
    <investigator>
      <last_name>Saad Jamshed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 27, 2013</lastchanged_date>
  <firstreceived_date>August 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rochester General Hospital</investigator_affiliation>
    <investigator_full_name>Saad Jamshed MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <keyword>Oncology</keyword>
  <keyword>Chemotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
